Syros Pharmaceuticals Inc. Daily Stock Analysis

Daily Stock Analysis, SYRS, Syros Pharmaceuticals Inc, priceseries

Syros Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
1.12
Close
1.02
High
1.12
Low
1.02
Previous Close
1.10
Daily Price Gain
-0.08
YTD High
3.85
YTD High Date
Jan 4, 2022
YTD Low
1.02
YTD Low Date
Mar 7, 2022
YTD Price Change
-2.78
YTD Gain
-73.16%
52 Week High
9.80
52 Week High Date
Mar 16, 2021
52 Week Low
1.02
52 Week Low Date
Mar 7, 2022
52 Week Price Change
-6.17
52 Week Gain
-85.81%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Mar 9. 2017
11.91
Mar 27. 2017
14.06
12 Trading Days
18.03%
Link
LONG
May 12. 2017
14.56
May 25. 2017
15.37
9 Trading Days
5.54%
Link
LONG
Jul 17. 2017
17.49
Aug 10. 2017
21.19
18 Trading Days
21.16%
Link
LONG
Jul 5. 2018
11.13
Jul 19. 2018
11.93
10 Trading Days
7.15%
Link
LONG
Mar 12. 2019
7.30
Mar 27. 2019
8.85
11 Trading Days
21.26%
Link
LONG
Aug 6. 2019
7.90
Aug 27. 2019
10.40
15 Trading Days
31.65%
Link
LONG
Dec 18. 2019
5.37
Jan 21. 2020
8.06
21 Trading Days
50.05%
Link
LONG
Apr 2. 2020
5.74
Apr 24. 2020
8.20
15 Trading Days
42.84%
Link
LONG
Jun 16. 2020
9.50
Jun 26. 2020
10.25
8 Trading Days
7.93%
Link
LONG
Aug 4. 2020
10.85
Aug 27. 2020
13.53
17 Trading Days
24.70%
Link
LONG
Nov 3. 2020
7.58
Nov 17. 2020
8.39
10 Trading Days
10.72%
Link
LONG
Dec 7. 2020
9.10
Dec 28. 2020
12.45
14 Trading Days
36.84%
Link
LONG
Jan 13. 2021
12.25
Jan 20. 2021
12.93
4 Trading Days
5.51%
Link
LONG
May 26. 2021
5.59
Jun 4. 2021
5.92
6 Trading Days
5.99%
Link
LONG
Aug 23. 2021
4.70
Sep 10. 2021
5.07
13 Trading Days
7.87%
Link
Company Information
Stock Symbol
SYRS
Exchange
NasdaqGS
Company URL
http://www.syros.com
Company Phone
617-744-1340
CEO
Nancy A. Simonian
Headquarters
Massachusetts
Business Address
620 MEMORIAL DRIVE, SUITE 300, CAMBRIDGE, MA 02139
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001556263
About

Syros Pharmaceuticals, Inc. engages in the development of novel gene control therapies for cancer and other diseases. Its platform identifies the master switches for disease genes, opening a whole new approach to novel therapeutics. The company focuses on treating disease by mapping gene regulatory circuits and modulating the factors that regulate gene expression. Syros Pharmaceuticals was founded by Richard A. Young, Nathanael S. Gray and James E. Bradner in 2012 and is headquartered in Cambridge, MA.

Description

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing medicines that control genes to transform the lives of patients with cancer, immune-mediated diseases, and other diseases. The company's gene control platform identifies gene control targets linked to genomically defined patient populations and drugging gene control targets; identifies potential new drug targets across a range of diseases; provides lens for diagnosing and segmenting patients, including those with complex/multi-factorial diseases; and allows users to advance a wave of medicines with the potential to influence multiple drivers of disease through a single target. Its pipeline includes SY-1425, a selective RARa agonist for genomically defined subsets of patients with relapsed or refractory acute myeloid leukemia and relapsed high-risk myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor for acute leukemia. Syros Pharmaceuticals, Inc. was formerly known as LS22, Inc. Syros Pharmaceuticals, Inc. was founded in 2011 and is based in Cambridge, Massachusetts.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading